Telix Pharma (TLX) Makes Progress With New Study [Yahoo! Finance]
Telix Pharmaceuticals Limited - American Depositary Shares (TLX)
Company Research
Source: Yahoo! Finance
Telix Pharmaceuticals Limited (NASDAQ:TLX) is a biotechnology company developing treatments for ailments such as prostate and kidney cancer. The firm's prostate cancer therapy candidate TLX591 is currently in a phase three study. On this front, Telix Pharmaceuticals Limited (NASDAQ:TLX) shared important news on December 8th when it announced that it had dosed the first patient in the study's part two. The phase three study is called ProstACT, and according to Telix Pharmaceuticals Limited (NASDAQ:TLX), part two will enroll roughly 490 patients. The firm will also share part one's results with the Food and Drug Administration (FDA) as part of its bid to bring the part two study to the US. Telix Pharmaceuticals Limited (NASDAQ:TLX) also made additional inroads to the US in September when it announced on the 23rd that it had received Medicare and Medicaid's Transitional Pass-Through payment status for its prostate cancer imaging agent Gozellix. This status means that hospitals will ge
Show less
Read more
Impact Snapshot
Event Time:
TLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TLX alerts
High impacting Telix Pharmaceuticals Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
TLX
News
- Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein ImmediatelyPR Newswire
- Telix Pharmaceuticals Ltd. Class Action: Levi & Korsinsky Reminds Telix Pharmaceuticals Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026 - TLXPR Newswire
- Levi & Korsinsky Reminds Telix Pharmaceuticals Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026 – TLXGlobeNewswire
- Robbins LLP Reminds Telix Pharmaceuticals Ltd. Stockholders About the January 9, 2026 Lead Plaintiff Deadline – Contact Us Today for Information About the TLX Class ActionBusiness Wire
- 21% TLX PLUNGE: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing FailuresPR Newswire
TLX
Sec Filings
- 12/8/25 - Form 6-K
- 10/14/25 - Form 6-K
- 9/23/25 - Form 6-K
- TLX's page on the SEC website